0 results available. Select is focused ,type to refine list, press Down to open the menu,
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the ...
The following section summarizes insights on GSK plc DRC's EV / EBITDA:
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to EV / EBITDA in the valuation category include:
Measures the dollars in Enterprise Value for each dollar of EBITDA over the last twelve months.
LTM EBITDA Multiple is defined as:
EBITDA Multiple = Enterprise Value / LTM EBITDA
Applying this formula, GSK’s EV/EBITDA Ratio is calculated below:
Enterprise Value [ £72.361 B ]
(/) EBITDA [ £8.313 B ]
(=) EV/EBITDA Ratio [ 8.7x ]
The tables below summarizes the trend in GSK’s EV/EBITDA Ratio over the last five years:
| Date | Enterprise Value | EBITDA | EV/EBITDA Ratio |
|---|---|---|---|
| 2020-12-31 | £94.05 B | £9.966 B | 9.4 |
| 2021-12-31 | £106 B | £8.334 B | 12.7 |
| 2022-12-31 | £71.258 B | £10.087 B | 7.1 |
| 2023-12-31 | £71.615 B | £8.744 B | 8.2 |
| 2024-12-31 | £72.361 B | £8.313 B | 8.7 |
EBITDA Multiple, Enterprise Value / EBITDA, or EV / EBITDA measures the dollars in Enterprise Value for each dollar of EBITDA.
EBITDA is used in the denominator since it is capital structure neutral and can be used to compare companies with different levels of debt (See EBITDA for benefits). We use Enterprise Value as the numerator to consider the claims on EBITDA of both debt and equity holders.
Strong revenue and EBITDA growth are highly correlated with higher EBITDA Multiples.
Read more about enterprise value (ev) and ebitda